Luminex Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Luminex stock.
View analyst ratings for Luminex or view top-rated stocks.

Wall Street analysts have given Luminex a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Luminex wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Luminex is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Luminex.

Luminex Co. (NASDAQ:LMNX) issued its earnings results on Sunday, February, 7th. The medical instruments supplier reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.12. The medical instruments supplier earned $111.39 million during the quarter, compared to the consensus estimate of $104.57 million. Luminex had a net margin of 4.60% and a trailing twelve-month return on equity of 3.75%. The company's revenue for the quarter was up 23.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.07 earnings per share.
View Luminex's earnings history.

Luminex's stock was trading at $27.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LMNX shares have increased by 21.7% and is now trading at $32.99.
View which stocks have been most impacted by COVID-19.

Luminex declared a quarterly dividend on Tuesday, February 9th. Shareholders of record on Thursday, March 25th will be given a dividend of $0.10 per share on Thursday, April 15th. This represents a $0.40 annualized dividend and a dividend yield of 1.21%. The ex-dividend date of this dividend is Wednesday, March 24th.
View Luminex's dividend history.

Luminex pays an annual dividend of $0.40 per share and currently has a dividend yield of 1.33%.
View Luminex's dividend history.

Luminex issued an update on its FY 2021 After-Hours earnings guidance on Monday, February, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $480-480 million, compared to the consensus revenue estimate of $474.36 million.

1 analysts have issued 1 year target prices for Luminex's shares. Their forecasts range from $38.00 to $38.00. On average, they expect Luminex's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 15.2% from the stock's current price.
View analysts' price targets for Luminex or view top-rated stocks among Wall Street analysts.

53 employees have rated Luminex CEO Nachum “Homi” Shamir on Glassdoor.com. Nachum “Homi” Shamir has an approval rating of 87% among Luminex's employees.

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), Bio-Techne (TECH), PerkinElmer (PKI), Charles River Laboratories International (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of LMNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include NVIDIA (NVDA), Baidu (BIDU), Cisco Systems (CSCO), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), Square (SQ), Marvell Technology Group (MRVL), AbbVie (ABBV) and CRISPR Therapeutics (CRSP).

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.55%), Dimensional Fund Advisors LP (3.96%), Copeland Capital Management LLC (2.98%), Renaissance Technologies LLC (1.41%), Bank of New York Mellon Corp (1.27%) and Northern Trust Corp (1.26%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, Randall Myers, Richard W Rew II and Stephen L Eck.
View institutional ownership trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Robeco Institutional Asset Management B.V., Dimensional Fund Advisors LP, Public Sector Pension Investment Board, Wells Fargo & Company MN, Russell Investments Group Ltd., Aviva PLC, and Glenmede Trust Co. NA. Company insiders that have sold Luminex company stock in the last year include G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, Randall Myers, and Richard W Rew II.
View insider buying and selling activity for Luminex or view top insider-selling stocks.

LMNX stock was acquired by a variety of institutional investors in the last quarter, including Copeland Capital Management LLC, BlackRock Inc., Tamarack Advisers LP, Frontier Capital Management Co. LLC, Investment Management of Virginia LLC, Amundi Pioneer Asset Management Inc., Morgan Stanley, and Crawford Investment Counsel Inc.. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, Nachum Shamir, and Stephen L Eck.
View insider buying and selling activity for Luminex or or view top insider-buying stocks.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LMNX stock can currently be purchased for approximately $32.99.

Luminex has a market capitalization of $1.53 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

Luminex employs 1,247 workers across the globe.

The official website for Luminex is www.luminexcorp.com.

Luminex is headquartered at 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]